Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

CADTH releases Recommendations Report for hepatitis C drugs

december 15, 2015

CDEC is a committee of the Canadian Agency for Drugs and Technologies in Health (CADTH). It makes recommendations and provides advice to Canadian jurisdictions to use in making informed decisions. It is made up of experts in drug evaluation and drug therapy, and public members.

CDEC has recently released its Recommendations Report for Drugs for Chronic Hepatitis C Infection.

In the report, CDEC puts forward 5 recommendations for Canadian jurisdictions seeking to list hepatitis C treatments: 

Recommendation 1: CDEC recommends that all patients with CHC infection should be considered for treatment, regardless of fibrosis score. Given the potential impact on health system sustainability of treating all patients with CHC infection on a first-come basis, priority for treatment should be given to patients with more severe disease.

Recommendation 2: CDEC recommends ledipasvir/sofosbuvir and paritaprevir/ritonavir/ombitasvir + dasabuvir ± ribavirin as preferred regimens for treatment-naive and peginterferon plus ribavirin (PR)- experienced patients with CHC genotype 1 infection, regardless of cirrhosis status. The recommended duration of therapy is as per the Health Canada–approved monograph for each regimen.

Conditions: Treatment should be initiated by physicians with experience in the management of patients with CHC infection.

Recommendation 3: CDEC recommends the following as preferred regimens for patients with CHC infection genotypes 2 through 4:  Genotype 2: sofosbuvir/ribavirin for 12 weeks  Genotype 3, without cirrhosis: daclatasvir/sofosbuvir for 12 weeks  Genotype 3, with cirrhosis: sofosbuvir/ribavirin for 24 weeks  Genotype 4, treatment-naive without cirrhosis: sofosbuvir/pegylated interferon/ribavirin for 12 weeks  Genotype 4, treatment-experienced or with cirrhosis regardless of treatment experience: insufficient evidence to make a recommendation.

Conditions: Treatment should be initiated by physicians with experience in the management of patients with CHC infection.

Recommendation 4: CDEC considered there to be insufficient evidence to make a recommendation for patients with CHC genotype 5 or 6 infection. 

Recommendation 5: CDEC recommends ledipasvir/sofosbuvir as the preferred regimen for patients with genotype 1 infection previously treated with a protease inhibitor-peginterferon/ribavirin regimen, regardless of cirrhosis status. CDEC considered there to be insufficient evidence to make a recommendation for patients previously treated with an all-oral DAA regimen. CDEC considered there to be insufficient evidence to make a recommendation for patients with non-genotype 1 CHC infection previously treated with a DAA-based regimen.

Conditions: Treatment should be initiated by physicians with experience in the management of patients with CHC infection.

You can read the full report here.